Go Pro
→ Buy These Stocks Before August 31st (From TradeSmith) (Ad)tc pixel Free MXCT Stock Alerts

MaxCyte (MXCT) Competitors

MaxCyte logo
GBX 1.38 -0.01 (-0.72%)
As of 08/20/2026
Compare

MXCT vs. VRCI, IDHC, DMTR, LLAI, and LLA

Should you buy MaxCyte stock or one of its competitors? MaxCyte's main competitors and comparable companies include Verici Dx (VRCI), Integrated Diagnostics (IDHC), Deepmatter Group (DMTR), LungLife AI (LLAI), and LLA.L,0P0001T9GN,0 (LLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MaxCyte compare to Verici Dx?

Verici Dx (LON:VRCI) and MaxCyte (LON:MXCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

In the previous week, Verici Dx's average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company Overall Sentiment
Verici Dx Neutral
MaxCyte Neutral

MaxCyte has a net margin of -119.69% compared to Verici Dx's net margin of -193.05%. MaxCyte's return on equity of -11.59% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-193.05% -138.93% -26.14%
MaxCyte -119.69%-11.59%-11.07%

Verici Dx has a beta of 1.256, indicating that its share price is 26% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

15.7% of Verici Dx shares are held by institutional investors. Comparatively, 24.0% of MaxCyte shares are held by institutional investors. 1.2% of Verici Dx shares are held by insiders. Comparatively, 1.9% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Verici Dx has higher earnings, but lower revenue than MaxCyte. Verici Dx is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.66M1.56-£6.56M-£0.90N/A
MaxCyte£32.29M0.05-£45.08M-£40.00N/A

Summary

MaxCyte beats Verici Dx on 7 of the 11 factors compared between the two stocks.

How does MaxCyte compare to Integrated Diagnostics?

Integrated Diagnostics (LON:IDHC) and MaxCyte (LON:MXCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Integrated Diagnostics has a beta of 0.436, indicating that its stock price is 56% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

In the previous week, Integrated Diagnostics' average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company Overall Sentiment
Integrated Diagnostics Neutral
MaxCyte Neutral

Integrated Diagnostics has a net margin of 17.20% compared to MaxCyte's net margin of -119.69%. Integrated Diagnostics' return on equity of 38.79% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.20% 38.79% 9.69%
MaxCyte -119.69%-11.59%-11.07%

Integrated Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
MaxCyte£32.29M0.05-£45.08M-£40.00N/A

7.7% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 24.0% of MaxCyte shares are held by institutional investors. 71.3% of Integrated Diagnostics shares are held by company insiders. Comparatively, 1.9% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Integrated Diagnostics beats MaxCyte on 8 of the 11 factors compared between the two stocks.

How does MaxCyte compare to Deepmatter Group?

MaxCyte (LON:MXCT) and Deepmatter Group (LON:DMTR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, MaxCyte's average media sentiment score of 0.00 equaled Deepmatter Group'saverage media sentiment score.

Company Overall Sentiment
MaxCyte Neutral
Deepmatter Group Neutral

Deepmatter Group has a net margin of 0.00% compared to MaxCyte's net margin of -119.69%. Deepmatter Group's return on equity of 0.00% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-119.69% -11.59% -11.07%
Deepmatter Group N/A N/A N/A

Deepmatter Group has lower revenue, but higher earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Deepmatter Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte£32.29M0.05-£45.08M-£40.00N/A
Deepmatter Group£1.04M0.00N/A-£0.30N/A

24.0% of MaxCyte shares are held by institutional investors. 1.9% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

MaxCyte and Deepmatter Group tied by winning 4 of the 8 factors compared between the two stocks.

How does MaxCyte compare to LungLife AI?

MaxCyte (LON:MXCT) and LungLife AI (LON:LLAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

MaxCyte has a net margin of -119.69% compared to LungLife AI's net margin of -11,767.39%. MaxCyte's return on equity of -11.59% beat LungLife AI's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-119.69% -11.59% -11.07%
LungLife AI -11,767.39%-51.42%-27.28%

24.0% of MaxCyte shares are held by institutional investors. Comparatively, 42.5% of LungLife AI shares are held by institutional investors. 1.9% of MaxCyte shares are held by company insiders. Comparatively, 48.4% of LungLife AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MaxCyte has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, LungLife AI has a beta of -0.3, suggesting that its stock price is 130% less volatile than the broader market.

LungLife AI has lower revenue, but higher earnings than MaxCyte. LungLife AI is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte£32.29M0.05-£45.08M-£40.00N/A
LungLife AI£33.87K34.24-£5.22M-£12.58N/A

In the previous week, MaxCyte's average media sentiment score of 0.00 equaled LungLife AI'saverage media sentiment score.

Company Overall Sentiment
MaxCyte Neutral
LungLife AI Neutral

Summary

MaxCyte beats LungLife AI on 6 of the 11 factors compared between the two stocks.

How does MaxCyte compare to LLA.L,0P0001T9GN,0?

LLA.L,0P0001T9GN,0 (LON:LLA) and MaxCyte (LON:MXCT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

In the previous week, LLA.L,0P0001T9GN,0's average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company Overall Sentiment
LLA.L,0P0001T9GN,0 Neutral
MaxCyte Neutral

5.4% of LLA.L,0P0001T9GN,0 shares are held by institutional investors. Comparatively, 24.0% of MaxCyte shares are held by institutional investors. 1.9% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LLA.L,0P0001T9GN,0 has a beta of -0.3, indicating that its share price is 130% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

LLA.L,0P0001T9GN,0 has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than LLA.L,0P0001T9GN,0, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LLA.L,0P0001T9GN,0N/AN/A-£4.47M-£0.12N/A
MaxCyte£32.29M0.05-£45.08M-£40.00N/A

LLA.L,0P0001T9GN,0 has a net margin of 0.00% compared to MaxCyte's net margin of -119.69%. MaxCyte's return on equity of -11.59% beat LLA.L,0P0001T9GN,0's return on equity.

Company Net Margins Return on Equity Return on Assets
LLA.L,0P0001T9GN,0N/A -48.59% -27.28%
MaxCyte -119.69%-11.59%-11.07%

Summary

MaxCyte beats LLA.L,0P0001T9GN,0 on 7 of the 10 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MXCT vs. The Competition

Export
MetricMaxCyteLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£1.47M£10.24B£7.37B£2.54B
Dividend YieldN/A1.46%2.53%6.17%
P/E Ratio-0.0361.54272.33367.57
Price / Sales0.05110.80613.1883,481.74
Price / Cash1.9727.0429.0327.89
Price / Book0.015.5611.257.19
Net Income-£45.08M£56.67B£3.47B£5.89B
7 Day Performance-0.72%4.19%2.33%0.42%
1 Month Performance21.05%11.38%7.72%3.03%
1 Year Performance-2.82%24.45%25.22%22.14%

MaxCyte Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MXCT
MaxCyte
N/AGBX 1.38
-0.7%		N/A-2.8%£1.47M£32.29MN/A80
VRCI
Verici Dx
N/AGBX 0.21
-16.0%		N/A-50.0%£4.80M£3.66MN/A19
IDHC
Integrated Diagnostics
N/AGBX 0.52
-0.4%		N/A+25.6%£3.01M£8.35B0.006,692
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04MN/AN/A
LLAI
LungLife AI
N/AGBX 3.50
-17.6%		N/A+0.0%£1.16M£33.87KN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:MXCT) was last updated on 8/24/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
A New Gold Era Is Coming - Here's How to Help Protect Your Retirement Now
Washington insiders are quietly talking about a coordinated move to revalue gold—and with the national debt ap...
Preserve Gold | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel